Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- GLP-1 receptor agonists like semaglutide and tirzepatide use precise milligram dosing, with low starting doses to reduce gastrointestinal side effects.
- Baseline labs, GI tolerance, and rate of weight loss guide the right GLP-1 peptide amount for each patient.
- Units on insulin syringes measure volume only. The actual milligram dose depends on vial concentration, so accurate conversion protects against dosing errors.
- Standard escalation schedules increase doses gradually each month, with regular monitoring of HbA1c, eGFR, liver enzymes, and lipids to maintain safety.
- Patients who want personalized, lab-guided GLP-1 care can book an appointment with Ellie at Mirror Plastic Surgery for supervised treatment from verified, batch-tested sources.
How GLP-1 Peptide Amounts Work
A GLP-1 receptor agonist dose is the quantity of active peptide delivered per injection, expressed in milligrams (mg). The amount determines how strongly the drug activates satiety signaling, slows gastric emptying, and modulates insulin release. Starting doses stay intentionally low to reduce gastrointestinal side effects, which commonly affect patients. The table below compares typical starting doses, maintenance ranges, and maximum doses for three major peptide options.
0.25 mg/week1.7–2.4 mg/week2.4 mg/week2.5 mg/week5–15 mg/week15 mg/week2 mg/week8–12 mg/week12 mg/week
| Peptide | Starting Dose | Maintenance Range | Maximum Dose |
|---|---|---|---|
| Semaglutide (weight mgmt.) | |||
| Tirzepatide (weight mgmt.) | |||
| Retatrutide / GLP-3R (investigational) |
Choosing the Right GLP-1 Dose for Your Body
GLP-1 peptide amounts must be individualized rather than copied from a standard plan. Most experts recommend using the lowest effective dose, which is the smallest amount that maintains a patient’s weight and metabolic goals. Several clinical factors shape the appropriate amount for each person.
Key individualization factors include:
- Baseline HbA1c, fasting glucose, eGFR, liver enzymes, and lipid panel results
- Gastrointestinal tolerance during escalation
- Rate of weight loss, and titration should pause if weight drops more than 1% of body weight per week
- Concurrent medications, particularly insulin or sulfonylureas
- History of pancreatitis, retinopathy, or gastroparesis
Dose increases occur no faster than once per month, and only when the patient is not experiencing significant side effects and is not losing weight too rapidly. This conservative approach reflects growing evidence that data-driven personalization of semaglutide therapy, based on labs and tolerance rather than a rigid schedule, improves outcomes compared with fixed-dose regimens.1
Reading Units and Milligrams on Your Syringe
Units on a U-100 insulin syringe measure volume only, not drug mass. One hundred units equal exactly 1 mL, so 1 unit equals 0.01 mL. The milligram dose depends entirely on the concentration of the solution in the vial.
The core conversion formula is:
Dose (mg) = (Units drawn ÷ 100) × Concentration (mg/mL)
To reverse the calculation and determine units to draw from a prescribed milligram dose, use:
Units = (Dose in mg ÷ Concentration in mg/mL) × 100
| Units Drawn (U-100 Syringe) | Concentration 2.5 mg/mL | Concentration 5 mg/mL | Concentration 10 mg/mL |
|---|---|---|---|
| 10 units | 0.25 mg | 0.5 mg | |
| 20 units | 0.5 mg | 1 mg | |
| 40 units | 1 mg | 2 mg |
Compounded semaglutide and tirzepatide are dispensed at various concentrations, so the same 20 units can deliver very different milligram doses. Always confirm the concentration printed on the vial label before drawing any dose.
How Much Is 40 Units of Semaglutide?
The meaning of 40 units depends entirely on the vial concentration. At 5 mg/mL, 40 units delivers 2 mg, which falls within the standard maintenance range for weight management. At 10 mg/mL, 40 units delivers 4 mg, which exceeds the approved maximum. At 2.5 mg/mL, 40 units delivers 1 mg, which fits mid-escalation dosing.
Dosing errors from syringe markings have led to FDA-documented overdoses. No unit amount can be labeled “a lot” or “a little” without first confirming the concentration of the specific compounded vial in hand.
How Much Is 20 Units of Semaglutide?
Twenty units on a U-100 insulin syringe always equals 0.2 mL of liquid volume, regardless of what is dissolved in it. As shown in the conversion table above, the milligram amount changes with concentration and ranges from 0.5 mg at the lowest concentration to 2 mg at the highest.
Before drawing any dose, verify the concentration printed on the vial label in the format “X mg/mL,” or calculate it by dividing total vial milligrams by the volume of bacteriostatic water used during reconstitution. For GLP-1 doses typically ranging from 0.05 mL to 0.25 mL, 30-unit or 50-unit syringes provide greater precision than 100-unit syringes, where each small line represents 2 units rather than 1.
Stepwise GLP-1 Escalation and Lab Monitoring
All three peptide classes use a slow, stepwise titration to reduce gastrointestinal side effects. Pause escalation if nausea, vomiting, or diarrhea becomes significant, or if weight loss exceeds 1% of body weight per week.
0.25 mg/week2.5 mg/week2 mg/week0.5 mg/week5 mg/week4 mg/week1 mg/week7.5 mg/week8 mg/week1.7 mg/week10 mg/week12 mg/week2.4 mg/week (maintenance)Up to 15 mg/week12 mg/week (max studied)
| Week Range | Semaglutide Dose | Tirzepatide Dose | Retatrutide Dose (Investigational) |
|---|---|---|---|
| Weeks 1–4 | |||
| Weeks 5–8 | |||
| Weeks 9–12 | |||
| Weeks 13–16 | |||
| Week 17+ |
Recommended lab markers to obtain at baseline and monitor during therapy include:
- HbA1c, with repeat testing every 3 months until targets are met, then at least twice yearly
- eGFR (serum creatinine), with monitoring within 4 weeks of initiation and 2–3 months after any dose increase
- Liver enzymes (ALT, AST), with baseline and periodic checks, especially in patients with suspected metabolic liver disease
- Lipid panel at baseline and at reassessment intervals
Pause criteria include persistent nausea or vomiting, suspected pancreatitis, rapid weight loss exceeding 1% body weight per week, or acute decline in eGFR. If three or more consecutive doses are missed, titration must restart from the lowest dose.
GLP-3R (Retatrutide) and Emerging Peptide Options
The term “GLP-3R” in compounding and wellness settings usually refers to retatrutide, a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors at the same time. Retatrutide is in Phase 3 clinical trials and is not yet FDA-approved, with regulatory submission expected in early 2027.
The glucagon receptor component increases hepatic energy expenditure and fat oxidation, which does not occur with semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist). Phase 3 TRIUMPH-4 data showed 28.7% mean weight loss at 68 weeks with the 12 mg dose.1 Reported GI side effects are dose-dependent, and nausea occurred in 36% at 4 mg, 44% at 8 mg, and 60% at 12 mg in Phase 2 trials.1
Because retatrutide remains investigational, any compounded version requires batch-tested sourcing and practitioner oversight. Retatrutide cannot be used in compounding under federal law, since it is not a component of any FDA-approved drug. Patients interested in next-generation GLP-1 options should review the current regulatory status with a qualified practitioner before moving forward.
Why Source GLP-1 Peptides Through a Regulated Clinic
Obtaining compounded GLP-1 peptides from unregulated online sources creates several documented safety risks.
- Dosing errors from concentration ambiguity: Concentration ambiguity can lead to dosing incidents with compounded GLP-1 medications.
- Adverse event reports: The FDA has received adverse event reports associated with compounded semaglutide and tirzepatide.
- Temperature control failures: The FDA has received complaints of compounded GLP-1 products arriving warm or with inadequate ice packs.
- Falsified products: The FDA has identified fraudulent compounded semaglutide and tirzepatide products with false pharmacy names or addresses on labels.
- Unofficial salt forms: Some compounded products use semaglutide sodium or semaglutide acetate, which differ from the active ingredients in FDA-approved drugs.
- Absence of lab monitoring: Without baseline and follow-up labs, contraindications such as pancreatitis history, retinopathy, or declining eGFR can go undetected.
Mirror Plastic Surgery sources peptides from reputable providers with rigorous batch testing, completes in-depth lab analysis before starting any protocol, and offers ongoing concierge support through Ellie Pranckevicius, FNP-BC.
Start your supervised GLP-1 protocol with Ellie, using only verified, batch-tested peptide sources.
Meet Ellie Pranckevicius, FNP-BC
Ellie Pranckevicius is a board-certified Family Nurse Practitioner and the lead practitioner for peptide therapies at Mirror Plastic Surgery in St. Petersburg, Florida. She holds a Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and earned both her Bachelor’s and Master’s in Nursing from the University of South Florida. Her clinical foundation includes four years in the Neuroscience ICU at Tampa General Hospital, where she developed deep expertise in physiology, metabolic health, and complex patient management.
Ellie began her career at a high-end medical spa in Boston, which gives her a dual perspective that bridges aesthetic goals with the clinical science required to achieve them safely. Her approach to GLP-1 peptide protocols centers on education. She explains the physiology behind each recommendation in accessible terms, reviews comprehensive lab panels before starting therapy, and provides 24/7 concierge support via text throughout the patient’s journey. When a service or escalation step is not yet warranted, she says so and prioritizes long-term metabolic outcomes over short-term revenue.
Key GLP-1 Terms Explained
- GLP-1 receptor agonist: A peptide that mimics the gut hormone glucagon-like peptide-1 and activates receptors that slow gastric emptying, reduce appetite, and stimulate glucose-dependent insulin release.
- Compounding: The process by which a licensed pharmacy prepares a customized medication, such as a specific concentration of semaglutide, outside of standard commercial manufacturing.
- Titration: The gradual, stepwise increase of a peptide dose over time to achieve therapeutic effect while limiting side effects.
- Units vs. milligrams: Units on a U-100 insulin syringe measure the volume of liquid drawn (1 unit = 0.01 mL). Milligrams measure the actual mass of active peptide in that volume. The two connect only through the vial’s concentration in mg/mL.
Frequently Asked Questions
Is it safe to use compounded GLP-1 peptides?
Compounded GLP-1 peptides can be used safely when they come from a state-licensed pharmacy that performs rigorous batch testing, are prescribed by a licensed clinician who has reviewed your medical history and lab results, and are administered under ongoing medical supervision. The main risks arise from unregulated online sources, where product purity, concentration accuracy, and temperature control cannot be verified. At Mirror Plastic Surgery, Ellie reviews comprehensive lab panels before starting any GLP-1 protocol and sources peptides exclusively from reputable, batch-tested providers.
How often should lab markers be monitored during GLP-1 therapy?
At baseline, a comprehensive metabolic panel including HbA1c, fasting glucose, eGFR, liver enzymes, and a lipid panel should be obtained. During the initial titration phase, gastrointestinal tolerance, weight, blood pressure, and renal markers should be assessed about every four weeks. Once a maintenance dose is reached, reassessment every three months, including HbA1c, eGFR, and urine albumin-to-creatinine ratio, is standard practice. Patients with a history of diabetic retinopathy need a retinal screening within six months of initiation because rapid HbA1c reduction can temporarily worsen retinopathy.
What strategies help preserve muscle mass during GLP-1 therapy?
Muscle loss during GLP-1 therapy is similar to that seen with diet-induced weight loss alone and is not unique to this drug class. It can be reduced through two main strategies. Patients should perform resistance training two to three times per week and aim for adequate protein intake of 1.2 to 1.6 grams per kilogram of ideal body weight daily. Slow titration also reduces the risk of excessive lean mass loss by preventing overly rapid weight reduction.1 Ellie incorporates body composition and muscle preservation guidance into every GLP-1 protocol at Mirror Plastic Surgery.
What happens if I need to pause or stop GLP-1 therapy?
If three or more consecutive weekly doses are missed, titration must restart from the lowest dose. Resuming at the prior dose after a long interruption increases the risk of severe gastrointestinal side effects. If therapy stops completely, the metabolic benefits, including appetite suppression and weight loss, gradually fade as the peptide clears the system.1 For patients who have reached their goals, a maintenance protocol at the lowest effective dose often works better than full discontinuation. Any decision to pause or stop should be made with your prescribing practitioner.
Who should not take GLP-1 receptor agonists?
Absolute contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), and a history of severe hypersensitivity to the specific GLP-1 agent. GLP-1 therapy requires caution, and sometimes avoidance, in patients with a history of pancreatitis, severe gastroparesis, uncontrolled proliferative diabetic retinopathy, or advanced chronic kidney disease. Pregnancy is also a contraindication because safety data remain limited. A thorough medical history review and baseline lab panel, as conducted by Ellie at Mirror Plastic Surgery, are essential before starting any GLP-1 protocol.
Summary: Safe GLP-1 Dosing With Personalized Support
GLP-1 peptide amounts are not interchangeable across individuals, vial concentrations, or peptide classes. Safe dosing requires knowing the exact concentration of the compounded product, applying the correct unit-to-milligram conversion, following a stepwise escalation schedule, and monitoring lab markers at defined intervals. The same 20 units drawn on a U-100 syringe can represent a wide range of milligram doses depending on the vial, which makes unsupervised self-dosing from online sources hazardous.
Mirror Plastic Surgery’s concierge model addresses each of these variables directly. Ellie Pranckevicius reviews your full medical history, orders or evaluates comprehensive lab panels, designs a personalized escalation schedule, and stays available throughout your protocol to adjust dosing based on your response. This approach reflects the standard of care that current evidence supports and the standard that patients in the St. Petersburg and Tampa Bay area deserve.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
